However, targeting MYC expression still represents an intervention option in prostate cancer, as demonstrated by the antisense-nucleotide approach in models of prostate cancer, where targeting MYC results in the suppression of proliferation and the reduction of prostasphere formation [24]. The gene discussed is MYC; the disease is Familial prostate cancer.